Perjeta

Perjeta

Perjeta is a personalised medicine approved by the FDA and EC in combination with Herceptin (trastuzumab) for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
Perjeta is designed to prevent the HER2 receptor from pairing with other HER receptors on the surface of cells, a mechanism that is complementary to Herceptin. Used together the combination is thought to provide a more comprehensive blockade of HER signalling pathways.